The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Discontinuation of immunotherapy over 2 years for patients with non–small cell lung cancer (NSCLC): A search for predictors.
 
Priscilla Cascetta
No Relationships to Disclose
 
Anna Reni
No Relationships to Disclose
 
Francesco Facchinetti
Consulting or Advisory Role - BeiGene
 
May-Lucie Meyer
No Relationships to Disclose
 
Mariona Riudavetz
No Relationships to Disclose
 
Mihaela Aldea
Consulting or Advisory Role - Viatris
Travel, Accommodations, Expenses - Sandoz
 
Filippo Gustavo Dall'Olio
No Relationships to Disclose
 
Arianna Marinello
No Relationships to Disclose
 
Marco Tagliamento
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Roche
Other Relationship - Amgen; MSD; Novartis
 
Jordi Remon Masip
Consulting or Advisory Role - AstraZeneca; Boehringer ingelheim; Bristol-Myers Squibb; Genmab; Janssen Oncology; Merck; MSD Oncology; OSE Immunotherapeutics; Pfizer; Roche/Genentech; Sanofi
Travel, Accommodations, Expenses - AstraZeneca; Inivata; OSE Immunotherapeutics; OSE Immunotherapeutics; Roche/Genentech
 
Benjamin Besse
Research Funding - Abbvie (Inst); Amgen (Inst); Aptitude Health (Inst); AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Ellipses Pharma (Inst); Genmab (Inst); Genzyme (Inst); Genzyme (Inst); Hedera Dx (Inst); Inivata (Inst); Ipsen (Inst); Janssen Oncology (Inst); MSD Oncology (Inst); PharmaMar (Inst); Roche/Genentech (Inst); Sanofi (Inst); socar (Inst); Taiho Pharmaceutical (Inst); Turning Point Therapeutics (Inst)
 
David Planchard
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Janssen; Lilly O.; Merck; Novartis; PeerVoice; Pfizer; prIME Oncology; Roche
Consulting or Advisory Role - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo Pharmaceutical; Janssen; Lilly O.; Merck; Novartis; PeerVoice; Pfizer; prIME Oncology; Roche
Research Funding - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo Pharmaceutical; Janssen; Lilly O.; MedImmune; Merck; Novartis; Novocure; Pfizer; Roche; Sanofi; Taiho Pharmaceutical
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer; Roche
 
Fabrice Barlesi
Consulting or Advisory Role - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai Europe (Inst); Lilly (Inst); Merck Serono (Inst); Mirati Therapeutics (Inst); MSD Oncology (Inst); Novartis (Inst); Roche/Genentech (Inst); Sanofi (Inst); Takeda (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Lisa Derosa
Honoraria - AstraZeneca; EverImmune; Regeneron; Sanofi
Consulting or Advisory Role - AstraZeneca; EverImmune; Regeneron; Sanofi
Research Funding - AstraZeneca; EverImmune; Regeneron; Sanofi